Navigation Links
Protein found to control tumor growth in certain breast cancers

This protein was previously thought to play a role solely in the innate immune system's response to bacterial infection. In the new study, which will be published on-line by the Proceedings of the National Academy of Sciences of the United States of America on January 23, researchers showed for the first time that the protein, which is present in epithelial cells of the intestinal tract and lungs, is linked to the control of malignant cell growth.

The study found that over-expression of the protein resulted in the nearly total inhibition of estrogen-dependent tumor growth in mice, and the reduction of estrogen-induced proliferative responses in vitro. In stark contrast, significant tumor growth occurred when Nod1 was absent.

"We have greatly expanded our knowledge of the Nod1 pathway beyond its known role in response to infection," said Richard J. Ulevitch, Ph.D. Ulevitch, who led the study, is a professor and chairman of the Scripps Research Department of Immunology. "These unexpected findings offer the first real evidence that this pathway may regulate tumor growth and suggest a potentially new mechanism for controlling this type of breast cancer. Unraveling the intricate mechanisms of this previously unknown pathway opens up the potential for future development of novel therapeutics, and will hopefully stimulate researchers to take a fresh look at the Nod1 protein."

In the study, researchers looked at a number of biological processes where Nod1-dependent apoptotic (programmed cell death) pathways were a critical component, including the regulation of tumor cell growth where the failure of malignant cells to undergo cell death led to tumorigenesis. Cells derived from the human breast cancer epithelial cell line MCF-7 ?the cellular model for estrogen sensitive breast cancer tumors ?were used to induce tumor growth in severe combined immunodeficiency (SCID) mice. An over-expression of Nod1 in MCF-7 cells resulted in the inhibition of estrogen-dependent tumor growth in the SCID mice and a reduction of estrogen-induced proliferative responses in vitro. Moreover, scientists found that the tumors diminished rapidly in these mice, becoming virtually undetectable by the end of the experiment.

In MCF-7 cells where Nod1 was absent, the tumors flourished. In addition, there was an increased sensitivity to estrogen-induced cell proliferation and a failure to undergo Nod1-dependent apoptosis in vitro.

Taking these initial findings one step further, researchers implanted estrogen pellets in the SCID mice to accelerate tumorigenesis. In those mice receiving Nod1 cell lines tumor growth did not occur even in the presence of estrogen pellets, indicating that Nod1 acts as an effective cellular brake on estrogen-dependent tumor growth. In addition, the presence of Nod1 reduced the expression of the naturally occurring estrogen receptor in vitro, further indication that the protein mediates the sensitivity of hormone-dependent breast cancer cells to tumorigenesis.

"While still preliminary, our data adds another critical function to Nod1," Ulevitch said, "namely its ability to regulate the growth of estrogen-sensitive tumors formed by specific cell lines in immune deficient mice. The evidence uncovered in this study provides new insights into the physiological functions of Nod1 and supports our contention that there is a clear link between Nod1 and estrogen sensitivity in these cells. Our future studies will assess the relationship between the pathway uncovered in breast cancer and other hormone sensitive malignancies. Those studies may help in the development of new therapeutic approaches with the potential to stabilize or even eradicate hormone-sensitive tumors."


'"/>

Source:Scripps Research Institute


Related biology news :

1. Quantum Dots Research Leads to New Knowledge about Protein Binding in Plants
2. Protein discovery could unlock the secret to better TB treatment
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. An HIV Protein Plays a Surprising Role in Gene Activation
5. Protein Packages Found To Activate Genes; May Be What Regulates Development And Disease
6. New SARS Protein Linked To Important Cell Doorway
7. The Shapes Of Life: NIGMS Project Yields More Than 1,000 Protein Structures
8. PANTHER Protein Classification System Database 5.0
9. Duke Chemists Isolating Individual Molecules Of Toxic Protein In Alzheimers, Parkinsons Disease
10. Newly Discovered Compound Blocks Known Cancer-Causing Protein
11. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: